Royal Bank of Canada
NDRM

Royal Bank of Canada’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Royal Bank of Canada’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-996
Closed -$39K – 7427
2017
Q3 		$39K Buy
996
+296
+42% +$10.9K ﹤0.01% 5568
2017
Q2 		$21K Hold
700
– – ﹤0.01% 5534
2017
Q1 		$19K Hold
700
– – ﹤0.01% 5671
2016
Q4 		$16K Hold
700
– – ﹤0.01% 5904
2016
Q3 		$13K Hold
700
– – ﹤0.01% 5713
2016
Q2 		$11K Hold
700
– – ﹤0.01% 5735
2016
Q1 		$10K Sell
700
-8,036
-92% -$109K ﹤0.01% 5753
2015
Q4 		$149K Buy
8,736
+8,036
+1,148% +$157K ﹤0.01% 4718
2015
Q3 		$14K Sell
700
-668
-49% -$13.7K ﹤0.01% 5750
2015
Q2 		$21K Buy
+1,368
New +$19.2K ﹤0.01% 5695

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $1.15B AUM 24.81% 1-Year Est. Return

Royal Bank of Canada's NDRM Position: Q4 2017 in Review

Royal Bank of Canada sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 996 shares — an estimated $39K sold.

Royal Bank of Canada first reported a position in NDRM in Q2 2015 and held it in 10 quarters. The position peaked at $149K in Q4 2015. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Royal Bank of Canada reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Royal Bank of Canada sold 996 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $39K.
  • Royal Bank of Canada first reported a position in NeuroDerm Ltd. Ordinary Shares in Q2 2015 and held it in 10 quarters.
  • Royal Bank of Canada's NeuroDerm Ltd. Ordinary Shares position peaked at $149K in Q4 2015.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Royal Bank of Canada's 13F filing for Q4 2017, filed 14 Feb 2018.